D. Nesta

发表

Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms.

C. Roberts, R. Brummitt, D. Nesta, 2011, Journal of pharmaceutical sciences.

Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.

Tony Lubiniecki, M. Rossi, P. Garidel, 2015, Biologicals : journal of the International Association of Biological Standardization.

Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.

Tony Lubiniecki, M. Rossi, P. Garidel, 2015, Journal of pharmaceutical sciences.

Evaluating Freeze–Thaw Processes in Biopharmaceutical Development

D. Nesta, G. Crotts, M. Puri, 2015 .

Identification of a variant collagen α3 (VI) in early-stage avian arteriosclerotic plaques

A. Penn, D. Nesta, 1995 .

Aggregation from Shear Stress and Surface Interaction Molecule-Specific or Universal Phenomenon?

D. Nesta, M. Haas, Tatiana Nanda, 2017 .

Enhanced expression of a high-molecular-weight protein in arteriosclerotic plaques.

A. Penn, D. Nesta, 1984, Atherosclerosis.

Japan-Specific Key Regulatory Aspects for Development of New Biopharmaceutical Drug Products.

D. Nesta, J. Colandene, K. G. Desai, 2018, Journal of pharmaceutical sciences.

Formulation Effects on Opalescence of a High-Concentration MAb

D. Nesta, J. Woods, 2010 .

An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.

S. Singh, M. Cromwell, L. Narhi, 2010, Journal of pharmaceutical sciences.

Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates.

Christopher J Roberts, T. Laue, C. Roberts, 2011, Journal of pharmaceutical sciences.

Unexplored benefits of controlled ice nucleation: Lyophilization of a highly concentrated monoclonal antibody solution

Ning Wang, Shubhadra N. Singh, D. Nesta, 2018, International journal of pharmaceutics.

Technical Considerations for Use of Oligonucleotide Solution API

Malcolm L Hill, Jale Muslehiddinoglu, Robert Simler, 2020, Nucleic acid therapeutics.

Transforming gene in human atherosclerotic plaque DNA.

A. Penn, S. Garte, D. Nesta, 1986, Proceedings of the National Academy of Sciences of the United States of America.

[3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells.

Laurence R. Meyerson, D. Nesta, 1991, Biochemical pharmacology.

Protein adsorption, desorption, and aggregation mediated by solid-liquid interfaces.

Christopher J Roberts, C. Roberts, D. Nesta, 2015, Journal of pharmaceutical sciences.

Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.

Christopher J Roberts, C. Roberts, R. Brummitt, 2011, Journal of pharmaceutical sciences.

Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration

Sorina Morar-Mitrica, Ping Hu, Manasi Puri, 2015, mAbs.

A method for routine analysis of recombinant immunoglobulins (rIgGs) by capillary isoelectric focusing (cIEF).

D. Nesta, K. Anumula, L. Maneri, 1999, Journal of pharmaceutical and biomedical analysis.

Supercritical fluid precipitation of recombinant human immunoglobulin from aqueous solutions.

D. Nesta, J. S. Elliott, J. Warr, 2000, Biotechnology and bioengineering.

Effects of temperature and osmolytes on competing degradation routes for an IgG1 antibody.

C. Roberts, D. Nesta, Nayoung Kim, 2013, Journal of pharmaceutical sciences.

Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration

D. Nesta, P. Hu, G. Crotts, 2015, mAbs.

Applications of isothermal titration calorimetry and differential scanning calorimetry in biopharmaceutical formulation development

D. Nesta, M. Puri, S. Morar-Mitrica, 2009 .